{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5360","value":"7910"},{"groupId":"OG001","spread":"64100","value":"41000"},{"groupId":"OG002","spread":"2720","value":"5990"},{"groupId":"OG003","spread":"2290","value":"5280"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Descriptive summary statistics (number, arithmetic mean, standard deviation \\[SDev\\], coefficient of variation \\[CV%\\]) for concentration and PK data for KW-2478 and Bortezomib in Phase 1 were presented by cohort, dose level and day.","dispersionType":"Standard Deviation","groups":[{"description":"Cohort 1: Both agents administered on Days 1, 4, 8, and 11 of a 21-day cycle with a standard 3+3 study design.","id":"OG000","title":"Phase 1 Cohort 1: KW-2478 130 mg/m^2 and Bortezomib 1.0mg/m^2"},{"description":"Cohort 2: Both agents administered on Days 1, 4, 8, and 11 of a 21-day cycle with a standard 3+3 study design.","id":"OG001","title":"Phase 1 Cohort 2: KW-2478 130 mg/m^2 and Bortezomib 1.3mg/m^2"},{"description":"Cohort 3: Both agents administered on Days 1, 4, 8, and 11 of a 21-day cycle with a standard 3+3 study design.","id":"OG002","title":"Phase 1 Cohort 3: KW-2478 175 mg/m^2 and Bortezomib 1.0mg/m^2"},{"description":"Cohort 4: Both agents administered on Days 1, 4, 8, and 11 of a 21-day cycle with a standard 3+3 study design.","id":"OG003","title":"Phase 1 Cohort 4: KW-2478 175 mg/m^2 and Bortezomib 1.3mg/m^2"}],"paramType":"MEAN","populationDescription":"The PK of KW-2478 was characterized after single administrations through @25 hours post start of infusion dose on Day 1 and through @7 hours post start of infusion dose on Day 11 in Phase 1 only.","reportingStatus":"POSTED","timeFrame":"PK collected Day 11 of 21-day cycle","title":"Phase 1: PK Exposure Cmax ng/mL Day 11","type":"SECONDARY","unitOfMeasure":"ng/mL"}